Monoamine Oxidase A and Catechol-O-Methyltransferase Functional Polymorphisms and the Placebo Response in Major Depressive Disorder
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The placebo response shows pronounced interindividual variability. Placebos are postulated to act through central reward pathways that are modulated by monoamines. Because monoaminergic signaling is under strong genetic control, we hypothesized that common functional polymorphisms modulating monoaminergic tone would be related to degree of improvement during placebo treatment of subjects with major depressive disorder. We examined polymorphisms in genes encoding the catabolic enzymes catechol-O-methyltransferase and monoamine oxidase A. Subjects with monoamine oxidase A G/T polymorphisms (rs6323) coding for the highest activity form of the enzyme (G or G/G) had a significantly lower magnitude of placebo response than those with other genotypes. Subjects with ValMet catechol-O-methyltransferase polymorphisms coding for a lower-activity form of the enzyme (2 Met alleles) showed a statistical trend toward a lower magnitude of placebo response. These findings support the hypothesis that genetic polymorphisms modulating monoaminergic tone are related to degree of placebo responsiveness in major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002) · Science · doi:10.1126/science.1067176 · Cited by 1,488 · cited 2×
“Unauthorized reproduction of this article is prohibited. experimental pain, with increases in metabolism and DA release reported in striatal structures including the NAC and the VTA.6,8 The present findings suggest that DA, NE, and perhaps serotonin (5-HT) signaling may be important to the placebo response in MDD as w…”
BackgroundThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“The activity of both MAO-A and COMT may be related to the ability of patients with MDD to experience reward.(32) No previous study has examined the outcome of placebo-treated subjects with MDD with regard to MAO-A activity.”
BackgroundA Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought
Price, D. D., Finniss, D. G., & Benedetti, F. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.113006.095941 · Cited by 1,146 · cited 2×
“Increased emotional reactivity to social cues in individuals with low-activity MAO-A could be consistent with the association between low-activity MAO-A and placebo response, in that emotional reactivity in the treatment situation is posited to be central to the placebo response.(1) There seem to be no studies on the…”
BackgroundResultDiscovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors
Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., Nichols, T. E., & Stohler, C. S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0439-05.2005 · Cited by 779 · cited 1×
“Subjects who were homozygous for the Met allele have been reported to have higher sensory and affective ratings of pain than those with at least 1 Val allele, and the Met-Met subjects also tended to show diminished mu-opioid system responses to pain than those with Val alleles.(37) Both of these findings would be cons…”
ResultBilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
Cited by
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Placebo and the New Physiology of the Doctor-Patient Relationship
Benedetti, F. (2013) · Physiological Reviews · doi:10.1152/physrev.00043.2012 · Cited by 492
“In another study in patients with major depressive disorder (209), polymorphisms in genes encoding the catabolic enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase A were examined.”
BackgroundHow Placebos Change the Patient's Brain
Benedetti, F., Carlino, E., & Pollo, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.81 · Cited by 446
“…the basis of the action of placebos on monoamines of the reward circuitry and because monoaminergic signaling is under strong genetic control, Leuchter et al (2009) examined the relationship between placebo responses and polymorphisms in genes encoding the catabolic enzymes…”
BackgroundSchedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“…been found to influence the individual placebo response in social anxiety at the behavioral and neural level (Furmark et al., 2008), and genetic polymorphisms modulating monoaminergic tone have been related to degree of placebo responsiveness in major depressive disorder (Leuchter et al., 2009).”
BackgroundHow placebo responses are formed: a learning perspective
Colloca, L., & Miller, F. G. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2010.0398 · Cited by 323
Placebo Effects: From the Neurobiological Paradigm to Translational Implications
Benedetti, F. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.023 · Cited by 317
Genetics and the placebo effect: the placebome
Hall, K. T., Loscalzo, J., & Kaptchuk, T. J. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.009 · Cited by 266
The placebo effect: From concepts to genes
Colagiuri, B., Schenk, L. A., Kessler, M. D., Dorsey, S. G., & Colloca, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.017 · Cited by 258
Tranylcypromine in mind (Part I): Review of pharmacology
Ulrich, S., Ricken, R., & Adli, M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.05.007 · Cited by 237
Placebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Role of expectations in health
Colloca, L., & Miller, F. G. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328343803b · Cited by 161
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
Zhang, W., Cao, C., Wang, M., Ji, L., & Cao, Y. (2016) · Journal of Youth and Adolescence · doi:10.1007/s10964-016-0442-1 · Cited by 50
Wendt, L., Albring, A., Benson, S., Engler, H., Engler, A., Hinney, A., Rief, W., Witzke, O., & Schedlowski, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107665 · Cited by 47
“Previously, functional polymorphisms in the monoamine oxidase gene (rs6323 G-allele at MAOA) and the COMT (Met allele at Val158Met) predicted reduced placebo responses in depression [21].”
BackgroundWang, M., Li, H., Deater-Deckard, K., & Zhang, W. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01079 · Cited by 19
Metadata
- Authors
- Leuchter, A. F., McCracken, J. T., Hunter, A. M., Cook, I. A., & Alpert, J. E.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-08
- Volume
- 29
- Issue
- 4
- Pages
- 372-377
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2054506460
- Cited by
- 123
- References
- 10
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.